TriangleObinutuzumab (NCT06108232)
Obinutuzumab trial for Follicular Lymphoma (NCT06108232). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously untreated, high-tumor-burden follicular lymphoma, grades 1–3a and stages II–IV.
The idea: combine intravenous obinutuzumab, which targets CD20 on B cells, with oral CC-99282. CC-99282 promotes breakdown of selected proteins and changes immune activity. Patients receive six 28-day cycles; disease assessment determines whether they continue for up to six more.
This phase 2 study plans 83 patients. Dai Chihara leads at MD Anderson Cancer Center in Houston, the sole recruiting US site. Researchers assess response and safety.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.